Lifecore Biomedical, Inc.
LFCR · NASDAQ
5/25/2025 | 5/26/2024 | 5/28/2023 | 5/29/2022 | |
|---|---|---|---|---|
| Revenue | $129 | $128 | $103 | $111 |
| % Growth | 0.5% | 24.2% | -7.2% | – |
| Cost of Goods Sold | $89 | $86 | $75 | $72 |
| Gross Profit | $40 | $42 | $28 | $39 |
| % Margin | 31.3% | 32.6% | 27.1% | 35.1% |
| R&D Expenses | $8 | $9 | $9 | $8 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $44 | $40 | $39 | $35 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $5 | $2 | $2 | $8 |
| Operating Expenses | $58 | $51 | $50 | $51 |
| Operating Income | -$17 | -$9 | -$22 | -$12 |
| % Margin | -13.4% | -6.9% | -21.1% | -10.6% |
| Other Income/Exp. Net | -$21 | $18 | -$42 | -$9 |
| Pre-Tax Income | -$39 | $10 | -$64 | -$21 |
| Tax Expense | $0 | $0 | $0 | -$5 |
| Net Income | -$39 | $12 | -$100 | -$117 |
| % Margin | -30% | 9.4% | -96.4% | -104.9% |
| EPS | -1.27 | 0.39 | -3.32 | -3.97 |
| % Growth | -425.6% | 111.7% | 16.4% | – |
| EPS Diluted | -1.27 | 0.33 | -3.32 | -3.97 |
| Weighted Avg Shares Out | 35 | 30 | 30 | 29 |
| Weighted Avg Shares Out Dil | 35 | 37 | 30 | 29 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $22 | $18 | $18 | $16 |
| Depreciation & Amortization | $8 | $8 | $13 | $18 |
| EBITDA | -$9 | $36 | -$33 | $13 |
| % Margin | -6.8% | 27.8% | -32.1% | 11.5% |